Fosamax is a bisphosphonate (i.e., drug that inhibits bone thinning and deterioration) manufactured and marketed by Merck and approved by the FDA in 1995 primarily to treat and prevent osteoporosis. Since its release, Fosamax has been prescribed to hundreds of millions of individuals, predominately post-menopausal women. In these cases, plaintiffs primarily allege dental or jaw-related injuries including osteonecrosis (ONJ). The latter condition, also referred to as bisphosphonate-induced osteonecrosis ("BONJ"), is alleged to causes the jaw bone to die, resulting in severe pain and, often, significant disfigurement.
- Administrative Guidelines
- Application for Mass Tort designation-Fosamax
- Supporting Application for Mass Tort designation-Fosamax
- Comments for Mass Tort designation